KCNMA1 and fragile X syndrome: In February 2025, Spinogenix (San Diego, CA, USA), a clinical-stage biopharmaceutical company, announced promising topline results from a Phase 2 clinical trial of SPG601, a small-molecule therapy targeting BK channels to correct synaptic dysfunction in FXS (NCT06413537) [171].